Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 8OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Other solid neoplasm 1Genitourinary 1

Conditions

Solid Tumors 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × TH 302 × Clear all
NCT01497444 2020-02-06

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Alliance for Clinical Trials in Oncology

Phase 1 Completed
24 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms

NCT01485042 2017-09-01

PATH

Duke University

Phase 1 Completed
50 enrolled
Other solid neoplasm

Solid Tumors

NCT02598687 2016-04-21

Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.

Maastricht Radiation Oncology

Phase 1 Withdrawn
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡